Merck to buy Sirna for $1.1 billion in cash (Reuters)
Reuters - Merck & Co. Inc. on Monday said it agreed to acquire biotechnology firm Sirna Therapeutics Inc. for $1.1 billion in cash to gain a stronger foothold in the promising drug-development technology of RNA interference.